does masshealth cover glp-1 As many Mass. residents face losing access to GLP-1s, local researchers dig into mental, physical impacts – The Bay State Banner A head's up that MassHealth

Take back control, quiet cravings, and hush your hunger

Results The first cohort included 36082 GLP-1 receptor agonist users (median follow-up 1.3 years) and 234028 DPP-4 inhibitor users (median follow-up 1.7 years)

The agency will continue to work with state regulators, monitor the market, and

Moderna's Covid-19 shot settlement, Prime Medicine's gene therapy, and other biotech news from The Readout

Methods This is a cohort study combining several population-wide databases and covering a Spanish population of five million inhabitants, including all adults with obesity who initiated treatment with either GLP-1RA or SGLT-2i for type 2 diabetes from 2015 to 2021

The growing prevalence of metabolic disease, CKD, and ASCVD have prompted investigation into the role of GLP-1R agonists in mitigating cardiovascular and metabolic risks, particularly within the framework of Cardiovascular-Kidney-Metabolic (CKM) Syndrome, irrespective of diabetic status